Post

New research · Ophthalmology
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 13h
Cohort studyJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026

Racial and Ethnic Disparities in Severe Ischemic Manifestations and Tocilizumab Use Among Patients With Giant Cell Arteritis: A Nationwide Retrospective Cohort Study Using TriNetX.

Daniel M Markowitz, Jose S Pulido, Jirat Nimworaphan … Robert C Sergott
Read paper
OphthalmologyCohort study

Black patients with giant cell arteritis less likely to receive tocilizumab than White patients

Racial and Ethnic Disparities in Severe Ischemic Manifestations and Tocilizumab Use Among Patients With Giant Cell Arteritis: A Nationwide Retrospective Cohort Study Using TriNetX.

Daniel M Markowitz … Robert C Sergott
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026
Background

Giant cell arteritis (giant cell arteritis) has traditionally been recognized as more common in White populations, but there is limited understanding of its epidemiology and severe ischemic manifestations in other racial and ethnic groups.

Purpose

This study investigated racial and ethnic differences in giant cell arteritis ischemic manifestations and tocilizumab use.

Methods

We conducted a retrospective cohort study using the TriNetX U.

Results

Black patients were much less likely than White patients to get this treatment

OR by subgroup · 95% CI
null = 1
less likely to receive tocilizumab
0.44
odds of ischemic optic neuropathy
0.61
receiving tocilizumab
0.51
blindness/low vision
0.45
More results

Hispanic patients had lower odds of ischemic optic neuropathy (OR: 0.61, 95% CI: 0.37-0.98) and receiving tocilizumab (OR: 0.51, 95% CI: 0.34-0.74) compared with White patients.

More results

Additionally, compared with White patients, Asian patients were less likely to be diagnosed with blindness/low vision (OR: 0.45, 95% CI: 0.27-0.76), had similar odds of ischemic optic neuropathy, and had no significant differences in tocilizumab use.

“
Conclusion · 1 of 2

There may be significant differences in severe ischemic manifestations of giant cell arteritis among non-White patients compared with White patients.

Conclusion · 2 of 2

There also appear to be differences in treatment with tocilizumab between Black and White patients and between Hispanic and White patients, but not between Asian and White patients.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment